William Blair Reiterates “Market Perform” Rating for Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF)‘s stock had its “market perform” rating reissued by William Blair in a research note issued to investors on Friday, Marketbeat reports.

A number of other research firms also recently commented on ZLDPF. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday. Four analysts have rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S presently has an average rating of “Buy”.

Zealand Pharma A/S Stock Down 30.7%

Shares of ZLDPF opened at $39.95 on Friday. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $101.29. The company’s fifty day moving average is $64.22 and its two-hundred day moving average is $70.69. The firm has a market cap of $2.84 billion, a PE ratio of 2.92 and a beta of 0.75. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%.The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. Analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Key Stories Impacting Zealand Pharma A/S

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait‑and‑see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell‑side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight‑loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight‑loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.